The Korean Journal of Internal Medicine10.3904/kjim.2017.0632019343608-617Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysisHong Deok Kim, Bum Jun Kim, Hyeong Su Kim, Jung Han Kim,,
Cancer Chemotherapy and Pharmacology10.1007/s00280-017-3411-92017804729-735Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and reviewJung Han Kim, Bum Jun Kim, Hyun Joo Jang, Hyeong Su Kim,,
Nuclear Medicine and Molecular Imaging10.1007/s13139-018-0548-32018526420-429Evaluation of RECIST, PERCIST, EORTC, and MDA Criteria for Assessing Treatment Response with Ga68-PSMA PET-CT in Metastatic Prostate Cancer Patient with Biochemical Progression: a Comparative StudyManoj Gupta, Partha Sarathi Choudhury, Sudhir Rawal, Harish Chandra Goel, S. Avinash Rao,,
European Journal of Nuclear Medicine and Molecular Imaging10.1007/s00259-017-3687-3201744S155-66Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developmentsKatja Pinker, Christopher Riedl, Wolfgang A. Weber,,
Journal of Gastrointestinal and Abdominal Radiology10.1055/s-0039-16920212019Tumor Response Criteria in Oncoimaging: RECIST Criteria and Beyond—Part 1Ashita Rastogi, Akshay D. Baheti, Anurima Patra, Sree Harsha Tirumani
Journal of Gastrointestinal and Abdominal Radiology10.1055/s-0039-16920162019Tumor Response Criteria in Oncoimaging: RECIST Criteria and Beyond—Part 2Akshay D. Baheti, Ashita Rastogi, Aravintho Natarajan, Anurima Patra, Sree Harsha Tirumani
European Journal of Nuclear Medicine and Molecular Imaging10.1007/s00259-016-3420-7201643111945-1953Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancerJingjie Shang, Xueying Ling, Linyue Zhang, Yongjin Tang, Zeyu Xiao, Yong Cheng, Bin Guo, Jian Gong, Li Huang, Hao Xu,,
Cancer10.1002/cncr.2625520111181147-156Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaJulien Edeline, Eveline Boucher, Yan Rolland, Elodie Vauléon, Marc Pracht, Christophe Perrin, Catherine Le Roux, Jean-Luc Raoul
Journal of Vascular and Interventional Radiology10.1016/j.jvir.2009.12.1702010212S13Abstract No. 27: Do the RECIST Amendment for Tumor Response Evaluation criteria correlate better with patient outcomes than the RECIST 1.1 criteria after conventional transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC)?P. Kranokpiraksa, J.R. Kachura, R. Beecroft, K. Tan, D.K. Rajan, J.D. Jaskolka,
Journal of Thoracic Oncology10.1016/j.jtho.2017.09.61820171211S1875-S1876MA 17.12 Comparison of EORTC, PERCIST, PeterMac & Deauville PET Response Criteria after Radical ChemoRT in Non-Small-Cell Lung CancerG. Turgeon, A. Iravani, T. Akhurst, J. Callahan, A. Cole, M. Bressel, S. Everitt, S. Siva, D. Ball, M. Mac Manus,